2,3-Benzodiazepine AMPA antagonists

Restorative Neurology and Neuroscience

Volumn 13, Issue 1-2, 1998, Pages 41-57

  Tarnawa, István ^a,c   Vizi, E Sylvester ^b  

^a Chinoin Pharmaceutical and Chemical Works Ltd   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NONE   (Hungary)

Author keywords

Epilepsy; GYKI 52466; Neurodegenerative disorders; Neuroprotection; Pain disorders; Spasticity

Indexed keywords

1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; BENZODIAZEPINE DERIVATIVE; CALCIUM ION; CYCLOTHIAZIDE; GLUTAMIC ACID; GYKI 53405; GYKI 53785; KAINIC ACID RECEPTOR; LY 303071; NERISOPAM; POTASSIUM CHANNEL; SODIUM CHANNEL; TALAMPANEL; TOFISOPAM; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; ATAXIA; CALCIUM CELL LEVEL; CARDIOVASCULAR FUNCTION; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; MIGRAINE; NEUROPROTECTION; NEUROTOXICITY; PAIN; PARKINSON DISEASE; POLYSYNAPTIC REFLEX; PRIORITY JOURNAL; PURKINJE CELL; RESPIRATORY FUNCTION; REVIEW; SCHIZOPHRENIA; SPASTICITY; SPREADING CORTICAL DEPRESSION; TREMOR; URINE INCONTINENCE; WITHDRAWAL SYNDROME;

EID: 0031733210     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (201)

1. Arvin, B., Moncada, C., Le Peillet, E., Chapman, A. and Meldrum, B.S. GYKI 52466 blocks the increase in extracellular glutamate induced by ischaemia. Neuroreport, 3 (1992) 235-238
2. Arvin, B., Lekieffre, D., Graham, J.L., Moncada, C., Chapman, A.G. and Meldrum, B.S. Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia. J. Neurochem., 62 (1994) 1458-1467
3. Barnes, J.M., Dev, K.K. and Henley J.M. Cyclothiazide unmask AMPA-evoked stimulation of [3H]-L-glutamate release from rat hippocampal synaptosomes. Br. J. Pharmacol., 113 (1994) 339-341
4. Berzsenyi, P., Tarnawa, I., Farkas, S. and Andrási, F. Pharmacology of a new centrally acting muscle relaxant. Pharmacol. Res. Commun., 20 (1988) 139-140
5. Bisaga, A., Krzascik, P., Jankowska, E., Palejko, W., Kostowski, W. and Danysz, W. Effect of glutamate antagonists on NMDA- and AMPA-induced behavioral effects in mice and rats. Eur. J. Pharmacol., 242 (1993) 213-220
6. Bleakman, D., Ballyk, B.A., Schoepp, D.D., Palmer, A.J., Bath, C.P., Sharpe, E.F., Woolley, M.L., Bufton, H.B., Kamboj, R.K., Tarnawa, I. and Lodge, D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereoselectivity and selectivity profiles. Neuropharmacology, 35 (1996) 1689-1702
7. Blochl, A. and Thoenen, H. Characterization of nerve growth factor (NGF) release from hippocampal neurons: evidence for a constitutive and an unconventional sodium-dependent regulated pathway. Eur. J. Neurosci., 7 (1995) 1220-1228
8. Block, F. and Schwarz, M. The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors. Eur. J. Pharmacol., 256 (1994) 149-153
9. Block, F., Schmitt, W. and Schwarz, M. Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats. J. Neurol. Sci., 139 (1996) 167-172
10. Block, F. and Schwarz, M. Correlation between hippocampal neuronal damage and spatial learning deficit due to global ischemia. Pharmacol. Biochem. Behav., 56 (1997) 755-761
11. Borowicz, K.K., Gasior, M., Kleinrok, Z.. and Czuczwar, S.J. The non-competitive AMPA/katnate receptor antagonist GYKI 52466 potentiates the anticonvulsant activity of conventional antiepileptics. Eur. J. Pharmacol., 281 (1995) 319-326
12. Bubser, M., Tzschentke, T. and Hauber, W. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J. Neural Transm., 101 (1995) 115-126
13. Buchan, A.M., Lesiuk, H., Barnes, K.A., Li, H., Huang, Z.G., Smith, K.E. and Xue, D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke, 24 (12 Suppl) (1993) 148-152
14. Budai, D. and Larson, A.A. GYKI 52466 inhibits AMPA/kainate and peripheral mechanical sensory activity. Neuroreport, 5 (1994) 881-884
15. Castillo, P.E., Malenka, R.C. and Nicoll, R.A. Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature, 388 (1997) 182-186
16. 2+ uptake in brain neurons. Eur. J. Pharmacol. Mol. Pharmacol. Sect., 290 (1995) 105-15
17. 2+ fluxes and neurotoxicity in rat cerebellar granule cells. Brain Res., 779 (1998) 194-204
18. Cebers, G., Zhivotovsky, B., Ankarcrona, M. and Liljequist, S. AMPA neurotoxicity in cultured cerebellar granule neurons: Mode of cell death. Brain Res. Bull., 43 (1998) 393-403
19. Chapman, A.C. Excitatory amino acid antagonists and therapy of epilepsy. In B.S. Meldrum (Ed). Excitatory amino acid antagonists, Blackwell, London. 1991. pp. 265-86.
20. Chapman, A.G., Smith, S.E. and Meldrum, B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res., 9 (1991) 92-96
21. Chapman, A.G., al-Zubaidy, Z. and Meldrum, B.S. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice. Eur. J. Pharmacol., 231 (1993) 301-303
22. Chen, Q., Harris, C., Brown, C.S., Howe, A., Surmeier, D.J. and Reiner, A. Glutamate-mediated excitotoxic death of cultured striatal neurons is mediated by non-NMDA receptors. Exp. Neurol., 136 (1995) 212-224
23. Chimirri, A., De Sarro, G., De Sarro, A., Gitto, R., Grasso, S., Quartarone, S., Zappala, M., Giusti, P., Libri, V., Constanti, A. and Chapman, A.G. 1-aryl-3,5-dihydro-4H-2,3-benzodiazepin-4-ones: Novel AMPA receptor antagonists. J. Med. Chem., 40 (1997) 1258-1269
24. Chittajallu, R., Vignes, M., Dev, K.K., Barnes, J.M., Collingridge, G.L. and Henley, J.M. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature, 379 (1996) 78-81
25. Chizh, B.A., Cumberbatch, M.J. and Headley, P.M. A comparison of intravenous GYKI 53655 and NBQX as AMPA antagonists in the rat spinal cord. Br. J. Pharmacol., 112 (1994) 843-846
26. Choi, D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1 (1988) 623-634
27. Clarke, V.R., Ballyk, B.A., Hoo, K.H., Mandelzys, A., Pellizzari, A., Bath, C.P., Thomas, J., Sharpe, E.F., Davies, C.H., Ornstein, P.L., Schoepp, D.D., Kamboj, R.K., Collingridge, G.L., Lodge, D. and Bleakman, D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature, 389 (1997) 599-603
28. Cowen, S.C. and Bean, P.M. Cyclothiazide and AMPA receptor desensitization: analyses from studies of AMPA-induced release of [3H]-noradrenaline from hippocampal slices. Br. J. Pharmacol., 123 (1998) 473-480
29. Croucher, M.J., Collins, J.F. and Meldrum, B.S. Anticonvulsant action of excitatory amino acid antagonists. Science, 216 (1982) 899-901
30. Cumberbatch, M.J., Chizh, B.A. and Headley, P.M. AMPA receptors have an equal role in spinal nociceptive and non-nociceptive transmission. Neuroreport, 5 (1994) 877-880
31. Cunha, R.A., Constantino, M.D. and Ribeiro, J.A. Inhibition of [3H]gamma-aminobutyric acid release by kainate receptor activation in rat hippocampal synaptosomes. Eur. J. Pharmacol., 323 (1997) 167-172
32. Czlonkowska, A., Siemiatkowski, M. and Plaznik, A. Some behavioral effects of AMPA/kainate receptor agonist and antagonists. J. Physiol. Pharmacol., 48 (1997) 479-488
33. ++ channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists. Eur. J. Pharmacol., 264 (1994) 103-106
34. Czuczwar, S.J., Borowicz, K.K., Kleinrok, Z., Tutka, P., Zarnowski, T. and Turski, W.A. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. Eur. J. Pharmacol., 281 (1995) 327-333
35. Czuczwar, S.J., Kleinrok, Z. and Turski, W.A. Interaction of calcium channel blockers and excitatory amino acid antagonists with conventional antiepileptic drugs. CNS Drug Rev., 2 (1996) 452-467
36. Danysz, W., Essmann, U., Bresink, I. and Wilke, R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol. Biochem. Behav., 48 (1994) 111-118
37. Danysz, W., Zajaczkowski, W. and Parsons, C.G. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol., 6 (1995) 455-474
38. Desai, M.A., Burnett, J.P. and Schoepp, D.D. Cyclothiazide selectively potentiates AMPA and kainate-induced (3H)norepinephrine release from rat hippocampal slices. J.Neurochem., 63 (1994) 231-237
39. Desai, M.A., Valli, M.J., Monn, J.A. and Schoepp, D.D. 1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices. Neuropharmacology, 34 (1995) 141-147
40. De Sarro, G., Chimirri, A., De Sarro, A., Gitto, R., Grasso, S., Giusti, P. and Chapman, A.G. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice. Eur. J. Pharmacol., 294 (1995) 411-422
41. Donevan, S.D. and Rogawski, M.A. GYKI 52466, a 2.3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron, 10 (1993) 51-59
42. Donevan, S.D., Yamaguchi, S.-I. and Rogawski, M.A. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J. Pharmacol. Exp. Ther., 271 (1994) 25-29
43. Dürmüller, N., Craggs, M. and Meldrum, B.S. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CCPene on the development of amygdala kindling and on amygdala kindled seizures. Epilepsy Res., 17 (1994) 167-174
44. Eckstein, J.A. and Swanson, S.P. Determination of a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist (LY300164) and its N-acetyl metabolite in mouse, rat, dog, and monkey plasma using high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. Biomed. Appl., 668 (1995) 153-158
45. Engberg, I., Tarnawa, I., Durand, J. and Ouardouz, M. An analysis of synaptic transmission to motoneurones in the cat spinal cord using a new selective receptor blocker. Acta Physiol. Scand., 148 (1993) 97-100
46. Erdõ, F. and Erdõ, S.L. Bimoclomol protects against vascular consequences of experimental subarachnoid hemorrhage in rats. Brain Res. Bull., 45 (1998) 163-166
47. 3H-aniracetam binds to specific recognition sites in brain meembranes; J. Neurochem., 65 (1995) 912-918
48. Farkas, S., Tarnawa, I., Berzsenyi, Pátfalusi, M., Andrási, F. and Ono, H. The role of non-NMDA excitatory amino acid receptors in the mediation of spinal reflexes. In K. Takai (Ed). Frontiers and New Horizons in Aminoacid Research, Elsevier, Amsterdam. 1992. pp. 471-475.
49. Farkas, S. and Ono, H. Participation of NMDA and non-NMDA excitatory amino acid receptors in the mediation of spinal reflex potentials in rats; an in vivo study. Br. J. Pharmacol., 114 (1995) 1193-1205
50. Fontana, G., De Bernardi, R., Ferro, F., Gemignani, A. and Raiteri, M. Characterization of the glutamate receptors mediating release of somatostatin from cultured hippocampal neurons. J. Neurochem., 66 (1996)161-168
51. 2+ channel inhibitors in mice. Pharmacol. Biochem. Behav., 56 (1997) 629-35
52. Gemignani, A., Marchese, S., Fontana, G. and Raiteri, M. Neuropeptide Y release from cultured hippocampal neurons: stimulation by glutamate acting at N-methyl-D-aspartate and AMPA receptors. Neuroscience, 81 (1997) 23-31
53. Gill, R., Foster, A.C. and Woodruff, G.N. MK-801 is neuroprotective in gerbils when administered during the postischemic period. Neuroscience, 25 (1988) 847-855
54. Gill, R. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc. Brain Metab. Rev., 6 (1994) 225-256
55. 2+ influx studies. J. Neurochem., 65 (1995) 1077-1084
56. Haefely, W., Pierry. L., Polc, P. and Schaffner, R. General pharmacology and neuropharmacology of benzodiazepine derivatives. In F. Hoffmeister and G. Stille (Eds). Handbook of Experimental Pharmacology, Vol. 55/II, Springer-Verlag, Berlin. 1981. pp. 13-262.
57. Hajnik, T., Détári, L. and Tarnawa, I. Effects of NMDA and non-NMDA glutamatergic drugs on EEG delta power and acoustic evoked potentials in freely moving rats. Eur. J. Neurosci., (1998) 54.51 (abstract)
58. Hauber, W. and Andersen, R. The non-NMDA receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmied. Arch. Pharmacol., 348 (1993) 486-490
59. Herlitze, S., Raditsch, M., Ruppensberg, J.P., Jahn, W., Monyer, H., Schoepfer, R. and Witzemann, V. Argiotoxin detects molecular differences in AMPA receptor channels. Neuron, 10 (1993) 1131-1140
60. Horváth, K., Andrási, F., Berzsenyi, P., Pátfalusi, M., Patthy, M., Szabó, G., Sebestyén, L., Kõrösi, J., Botka, P., Hámori, T. and Láng, T. A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity. Arzneim. Forsch. Drug. Res., 39 (1989) 894-899
61. Horvath, K., Szabo, H., Patfalusi, M., Berzsenyi, P. and Andrasi, F. Pharmacological effects of GYKI 52895, a new selective dopamine uptake inhibitor. Eur. J. Pharmacol., 183 (1990) 1416-1417
62. 2+ in cultured neurons from rat brain. J. Neurochem., 64 (1995) 2049-2056
63. Ikonomidou, C. and Turski, L. Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-(F)-quinoxaline. Ann. N.Y. Acad. Sci., 825 (1997) 394-402
64. Impagnatiello, F., Oberto, A., Longone, P., Costa, E. and Guidotti, A. 7-Chloro 3-methyl 3,4-dihydro 2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity. Proc. Natl. Acad. Sci. U.S.A., 94 (1997) 7053-7058
65. Jackson, A., Brown, G. and Stephens, D.N. N-methyl-D-aspartate (NMDA) and alpha-amino-S-hydroxy-S-methyl-4-isoxazoleproprionate (AMPA) glutamate-receptor antagonists have different interactions with the discriminative stimuli of abused drugs. Psychopharmacology (Berl), 128 (1996) 320-327
66. Jaw, S.P., Nguyen, B., Vuong, Q.-T.V., Trinh, T.A., Guyen, M. and Truong, D.D. Effects of glutamate receptor antagonists on posthypoxic myoclonus in rats. Brain Res. Bull., 40 (1996) 163-166
67. Jensen, J.B., Schousboe, A. and Pickering D.S. AMPA receptor mediated excitotoxicity in neocortical neurons is developmentally regulated and dependent upon receptor desensitization. Neurochem. Int., 32 (1998) 505-513
68. Johansen, T.H., Chaudhary, A. and Verdoorn, T.A. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol. Pharmacol., 48 (1995) 946-955
69. Kamisaki, Y., Hamada, T., Maeda, K., Ishimura, M. and Itoh, T. Presynaptic 2 adrenoceptors inhibit glutamate release from rat spinal cord synaptosomes. J. Neurochem., 60 (1993) 522-526
70. 2+ concentration in isolated nerve terminals following metabolic inhibition: possible relevance to hypoglycaemia and anoxia. Neuroscience. 27 (1988) 175-182
71. Kessler, M., Arai, A., Quan, A. and Lynch, G. Effect of cyclothiazide on binding properties of AMPA-type glutamate receptors: lack of competition between cyclothiazide and GYKI 52466. Mol. Pharmacol., 49 (1996) 123-131
72. Klarica, M., Fage, D. and Carter, C. Pharmacology of N-methyl-D-aspartase-evoked [3H] noradrenaline relesae in adult rat spinal cord. Eur. J. Pharmacol., 308 (1996) 135-139
73. Klockgether, T. and Turski, L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci., 12 (1989) 285-286
74. Kovacs, A.D. and Szabo, G. GYKI 53655, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity. Eur. J. Pharmacol., 331 (1997) 93-96
75. Kovacs, A.D. and Szabo, G. Comparison of neuroprotective efficacy of competitive and non-competitive AMPA antagonists in vitro. Environ. Toxicol. Pharmacol., 3 (1997) 69-72
76. Kubova, H., Vilagi, I., Mikulecka, A. and Mares, P. Non-NMDA receptor antagonist GYKI-52466 suppresses cortical afterdischarges in immature rats. Eur. J. Pharmacol., 333 (1997) 17-26
77. Launey, T., Ivanov, A., Ferrand, N. and Gueritaud, J.-P. Developing rat brainstem motoneurones in organotypic culture express calcium permeable AMPA-gated receptors. Brain Res., 781 (1998) 148-158
78. Launey, T., Ivanov, A., Kapus, G., Ferrand, N., Tarnawa, I. and Gueritaud, J.-P. Excitatory amino acids and synaptic transmission in embryonic rat brainstem motoneurones in organotypic culture. Eur. J. Neurosci., (submitted)
79. Le Peillet, E., Arvin, B., Moncada, C. and Meldrum, B.S. The non-NMDA antagonists, NBQX and GYKI 52466 protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res., 571 (1992) 115-120
80. Leander, J.D. Behavioral pharmacology of non-competitive AMPA receptor antagonists. Proc. Behav. Pharmacol. Soc. Cambridge, USA 1994 (abstract)
81. Lerma, J., Morales, M., Vicente, M.A. and Herreras, O. Glutamate receptors of the kainate type and synaptic transmission. Trends. Neurosci., 20 (1997) 9-12
82. Li, H. and Buchan, A.M. Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab., 13 (1993) 933-939
83. Li, W., Czilli, D.L. and Simmons, K.L. Structural analogs of the non-NMDA receptor antagonist GYKI 52466 depress K+ currents in hippocampal neurons. Soc. Neurosci. Abs., 20 (1994) 630.13. (abstract)
84. Li, F., Owens, N. and Verdoorn, T.A. Functional effects of mutations in the putative agonist binding region of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Mol. Pharmacol. 47 (1995) 148-154
85. 2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons. Biochem. Pharmacol., 50 (1995) 1761-1774
86. Ling, I., Podányi, B., Hámori, T. and Sólyom S. Asymmetric reduction of carbon-nitrogen double bond: Enantioselective synthesis of 3,4-Dihydro-5H-2,3-benzodiazepines. J. Chem. Soc., Perkin Trans., 1 (1995) 1423-1427
87. Ling, I., Ábrahám, G., Sólyom, S., Hámori, T., Tarnawa, I., Berzsenyi, P., Andrási, F., Csuzdi, E., Szöllõsi, M., Simay, A., Pallagi, I. and Horváth, K. 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors. WO 9728135 (1997) (patent)
88. 2+ influx in oligodendrocyte progenitors. Eur. J. Pharmacol., 338 (1997) 277-287
89. Liu, X.H., Wang, P. and Barks, J.D.E. The non-competitive AMPA antagonist LY 300168 (GYKI 53655) attenuates AMPA-induced hippocampal injury in neonatal rodents. Neurosci. Lett., 235 (1997) 93-97
90. Lodge, D., Jones, M.G., Palmer, A.J. and Zeman, S. Electropharmacology of excitatory amino acids; In K. Takai (Ed). Frontiers and New Horizons in Aminoacid Research, Elsevier, Amsterdam. 1992. pp. 231-238.
91. Lodge, D., Bond, A., O'Neill, M.J., Hicks, C.A. and Jones, M.G. Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies. Neuropharmacology, 35 (1996) 1681-1688
92. Lombardi, G., Moroni, F. and Moroni, F. Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur. J. Pharmacol., 271 (1994) 489-495
93. Lonart, G. and Johnson, K.M. Characterization of nitric oxide generator-induced hippocampal 3H-norepinephrine release. I. The role of glutamate. J. Pharmacol. Exp. Ther., 275 (1995) 7-13
94. Löscher, W. and Hönack, D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol., 113 (1994) 1349-1357
95. Löschmann, P.-A., Lange, K.W., Kunow, M., Rettig, K.-J., Jahnig, P., Honore, T., Turski, L., Wachtel, H., Jenner, P. and Marsden, C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J. Neural. Transm. 3 (1991) 203-213
96. Lu, Y. and Wehner, J.M. Enhancement of contexual fear-conditioning by putative (+/-)-alpha-amino 3-hyroxy 5-methylisoxazole 4-propionic acid (AMPA) receptor modulators and N-methyl-D-aspartate (NMDA) receptor antagonists in DBA/2J mice. Brain Res., 768 (1997) 197-207
97. Lukasiewicz, P.D., Wilson, J.A. and Lawrence, J.E. AMPA-preferring receptors mediate excitatory synaptic inputs to retinal ganglion cells. J. Neurophys., 77 (1997) 57-64
98. Magazanik, L.G., Buldakova, S.L., Samoilova, M.V., Gmiro, V.E., Mellor, I.R. and Usherwood, P.N.R. Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. J. Physiol., 505 (1997) 655-663
99. Malva, J.O., Carvalho, A.P. and Carvalho, C.M. Kainate receptors in hippocampal CA3 subregion: evidence for a role in regulating neurotransmitter release. Neurochem. Int., 32 (1998) 1-6
100. 2+ channels. Neurochem. Int., 32 (1998) 7-16.
101. Matsumoto, G., Hisamitsu, T. and de Groat W.C. Non-NMDA glutamatergic excitatory transmission in the descending limb of the bulbospinal micturition reflex pathway of the rat. Brain Res., 693 (1995) 246-250
102. May, P.C. and Robinson, P.M. Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures. J. Neurochem., 60 (1993) 1171-1174
103. Meldrum, B.S. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clinical Sci., 68 (1985) 113-122
104. Meldrum, B.S., Craggs, M.D., Dürmüller, N., Smith, S.E. and Chapman A.C. The effects of AMPA receptor antagonists on kindled seizures and on reflex epilepsy in rodents and primetes. Epilepsy Res. Suppl., 9 (1992) 307-311
105. Meldrum, B. and Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci., 11 (1990) 379-387
106. Miller, R.J. The revenge of the kainate receptor. Trends Neurosci., 14 (1991) 477-479
107. 3H]dopamine in rat striatal slices. Neurochem. Int., 28 (1996) 501-507
108. Milusheva, E., Doda, M., Pasztor, E., Lajtha, A., Sershe, H. and Vizi, E.S. Regulatory interactions among axon terminals affecting the release of different transmitters from rat striatal slices under hypoxic and hypoglycemic conditions. J. Neurochem., 59 (1992) 946-952
109. Mike, A., Dyatlov, V.A. and Vizi, E.S. Non-NMDA receptor-mediated modulation of voltage-activated outward currents in chick neurones. Neuroreport,. 7 (1996) 2613-2617
110. Moncada, C., Arvin, B., Le Peillet, E. and Meldrum, B.S. Non-NMDA antagonists protect against kainate more than AMPA toxicity in the rat hippocampus. Neurosci. Lett., 133 (1991) 287-290
111. Nakai, T., Milusheva, E., Baranyi, M., Uchihashi, Y., Satoh, T. and Vizi, E.S. Excessive release of -noradrenaline and glutamate in response to simulation of ischemic condition in rat spinal cord slice preparation: Effect of NMDA and AMPA receptor antagonists. Eur. J. Pharmacol., (in press)
112. Nucci, C., Piccirilli, S., Bagetta, G., Nistico, G. and Cerulli, L. N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor antagonists protect from apoptosis induced in the lateral geniculate nucleus of rabbits exposed to the dark. Neurosci. Lett., 229 (1997) 185-188
113. Oh, S. and McCaslin, P.P. Kainate produces concentration-dependent elevation of glutamate release but not cGMP levels in cultired neuron. Gen. Pharmacol., 27 (1996) 87-87
114. Ohno, K., Okada, M., Tsutsumi, R., Matsumoto, N. and Yamaguchi, T. Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures. Neurochem. Int., 32 (1998) 265-271
115. Okada, M., Kohara, A. and Yamaguchi, T. Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes. Eur. J. Pharmacol., 309 (1996) 299-306
116. Osipenko, O., Mike, Å., Gyévai, A. and Vizi, E.S. Evidence that GYKI 53466, a novel non-NMDA antagonist enhances the desensitization rate to kainate in cultured chicken cortical neurons. Develop. Brain Res., 77 (1994) 257-263
117. Ouardouz, M. and Durand, J. GYKI 52466 antagonizes glutamate responses but not NMDA and kainate responses in rat abducens motoneurones. Neurosci. Lett., 125 (1991) 5-8
118. Ouardouz, M. and Durand J. Involvement of AMPA receptors in trigeminal postsynaptic potentials recorded in rat abducens motoneurons in vivo. Eur. J. Neurosci., 6 (1994) 1662-1668
119. Palmer, A.J. and Lodge, D. Cyclothiazide reverses AMPA receptor antagonism of the 2,3-benzodiazepine, GYKI 53655. Eur. J. Pharmacol., 244 (1993) 193-194
120. Parsons, C.G., Gruner, R. and Rozental, J. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline (NBQX) and 1(4-amino-phenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzodiazepine (GYKI 52466). Neuropharmacology, 33 (1994) 589-604
121. Partin, K.M. and Mayer, M.L. Negative allosteric modulation of wildtype and mutant AMPA receptors by GYKI 53655. Mol. Pharmacol., 49 (1996) 142-148
122. Patel, D.R. and Croucher, M.J. Evidence for a role of presynaptic AMPA receptors in the control of neuronal glutamate release in the rat forebrain. Eur. J. Pharmacol., 332 (1997) 143-151
123. Paternain, A.V., Morales, M. and Lerma, J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron, 14 (1995) 185-189
124. Pearce, P.C., MacLean, C.J., Shergill, H.K., Ward, E.M., Halsey, M.J., Tindley, G., Pearson, J. and Meldrum, B.S. Protection from high pressure induced hyperexcitability by the AMPA/kainate receptor antagonists GYKI 52466 and LY 293558. Neuropharmacology, 33 (1994) 605-612
125. 2+-permeable AMPA receptors in neurological disorders. Trends Neurosci., 20 (1997) 464-470
126. Pelletier, J.C., Hesson, D.P., Jones, K.A. and Costa, A.-M. Substituted 1,2-dihydrophthalazines: Potent, Selective, and noncompetitive inhibitors of the AMPA receptor. J. Med. Chem., 39 (1996) 343-346
127. 3H] dopamine release from rat mesencephalic cells in primary culture. J. Neurochem., 64 (1995)1410-1412
128. Petitet, F., Blanchard, J.C. and Doble, A. Effects of AMPA receptor modulators on the production of arachidonic acid from striatal neurons. Eur. J. Pharmacol., 291 (1995) 143-151
129. Phillis, J.W. and Smith-Barbour, M. GYKI 52466 and ischemia-evoked neurotransmitter amino acid release from rat cerebral cortex. Neuroreport, 4 (1993) 109-111
130. Pierrefiche, O., Foutz, A.S., Champagnat, J. and Denavit-Saubié, M. NMDA and non-NMDA glutamate receptors may play distinct roles in timing mechanisms and transmission in the feline respiratory network. J. Physiol., 474 (1994) 509-523
131. Prehn, J.H.M., Lippert, K. and Krieglstein, J. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury. Eur. J. Pharmacol., 292 (1995) 179-189
132. Rammes, G., Parsons, C., Müller, W. and Swandula, D. Modulation of fast excitatory synaptic transmission by cyclothiazide and GYKI 52466 in the rat hippocampus. Neurosci. Lett., 175 (1994) 21-24
133. Rammes, G., Swandulla, D., Collingridge, G.L., Hartmann, S. and Parsons, C.G. Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. Br. J. Pharmacol., 117 (1996) 1209-1221
134. Regan, R.F. The vulnerability of spinal cord neurons to excitotoxic injury: Comparison with cortical neurons. Neurosci. Lett., 213 (1996) 9-12
135. Renard, A., Crépel, F. and Audinat, E. Evidence for two types of non-NMDA receptors in rat cerebellar Purkinje cells maintained in slice cultures. Neuropharmacology, 34 (1995) 335-346
136. Rogawski, M.A. Therapeutical potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci., 14 (1993) 325-331
137. Rothstein, J.D., Jin, L., Dykes-Hoberg, M. and Kuncl, R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA, 90 (1993) 6591-6595
138. Rothstein, J.D., Bristol, L.A., Hosler, B., Brown, R.H., Jr. and Kuncl, R.W. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc. Natl. Acad. Sci. USA, 91 (1994) 4155-4159
139. Ruiz, A. and Durand, J. Modulation of kainate-induced responses by pentobarbitone and GYKI 53784 in rat abducens motoneurons in vivo. Eur. J. Neurosci., (submitted)
140. Sajdyk, T.J. and Shekhar, A. Excitatory amino acid receptor antagonists block the cardiovascular and anxiety responses elicited by gamma-aminobutyric acid, receptor blockade in the basolateral amygdala of rats. J. Pharmacol. Exp. Ther., 283 (1997) 969-977
141. Saji, M., Kimura, M., Ishida, G. and Ohno, K. Deafferentation-induced c-fos gene expression in subthalamic nucleus and substantia nigra reticulata is reduced by non-NMDA receptor antagonist. Brain Res., 703 (1995) 165-174
142. Salamon, C., Horvath, E.J., Fekete, M.I. and Aranyi, P. A novel specific binding site for anxiolytic homophthalazines in the rat brain. FEBS Lett., 308 (1992) 215-217
143. Savidge, J.R., Bleakman, D. and Bristow, D.R. Identification of kainate receptor-mediated intracellular calcium increases in cultured rat cerebellar granule cells. J. Neurochem., 69 (1997) 1763-1766
144. Schoepp, D.D., Lodge, D., Bleakman, D., Leander, J.D., Tizzano, J.P., Wright, R.A., Palmer, A.J., Salhoff, C.R. and Ornstein, P.L. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-2-(1(2)H-tetrazole-5-yl)ethyldecahydroisoquinoline-3- carboxylic acid. Neuropharmacology, 34 (1995) 1159-1168
145. Schurr, A., Payne, R.S., Heine, M.F. and Rigor, B.M. Hypoxia, excitotoxicity, and neuroprotection in the hippocampal slice preparation. J. Neursci. Meth., 59 (1995) 129-138
146. Sharp, R.L., May, P.C., Mayne, N.G., Snyder, Y.M. and Burnett, J.P. Cyclothiazide potentiates agonist responses at human AMPA/kainate receptors expressed in oocytes. Eur. J. Pharmacol. Molec. Pharm. Sect., 266 (1994) R1-2
147. Sheardown, M.J. The triggering of spreading depression in the chicken retina: a pharmacological study. Brain Res., 607 (1993) 189-194
148. Sheardown, M J., Nielsen, E.O., Hansen, A.J., Jacobsen, P. and Honore, T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science, 247 (1990) 571-574
149. Shimizu-Sasamata, M., Kawatsagi-Yatsugi, S. and Okada, M. YM90K: Pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther., 276 (1996) 84-92
150. Slusher, B. S., Rissolo, K.C., Anzilotti, K.F., Jr. and Jackson, P.F. Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats. J. Neural Transm. Park. Dis. Dement. Sect., 9 (1995) 145-149
151. Smith, S.E., Durmuller, N. and Meldrum, B.S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol., 201 (1991) 179-183
152. Smith, S.E. and Meldrum, B.S. Receptor site specificity for the acute effects of beta-N-methylamino-alanine in mice. Eur. J. Pharmacol., 187 (1990) 131-134
153. Smith, S.E. and Meldrum, B.S. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischaemia in the rat. Stroke, 23 (1992) 861-864
154. Snell, L.D., Yi, S.J. and Johnson, K.M. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur. J. Pharmacol., 145 (1988) 223-226
155. Staubli, U., Rogers, G. and Lynch, G. Facilitation of glutamate receptors enhances memory. Proc. Natl. Acad. Sci. USA, 91 (1994) 777-781
156. Stephens, D.N. and Cole, B.J. AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks. Psychopharmacology, 126 (1996) 249-259
157. Steppuhn, K.G. and Turski, L. Diazepam dependence prevented by glutamate antagonists. Proc. Natl. Acad. Sci. USA, 90 (1993) 6889-6893
158. Steppuhn, K.G. and Turski, L. Modualation of the seizue threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther., 265 (1993) 1063-1070
159. Strahlendorf, J.C., Acosta, S. and Strahlendorf, H.K. Diazoxide and cyclothiazide convert AMPA-induced dark cell degeneration of Purkinje cells to edematous damage in the cerebellar slice. Brain Res., 729 (1996) 197-204
160. 3H-GYKI 53405 to Xenopus brain membranes. Neuroreport, 5 (1993) 93-94
161. Szekely, J.I., Kedves, R., Mate, I., Török, K. and Tarnawa, I. Apparent antinociceptive and anti-inflammatory effects of GYKI52466. Eur. J. Pharmacol., 336 (1997) 143-154
162. Tarnawa, I., Berzsenyi, P., Andrasi, F., Botka, P., Hámori, T., Ling, I. and Körösi, J. Structure-activity relationships among 2,3-benzodiazepine compounds with AMPA antagonistic action. Bioorg. Med. Chem. Lett., 3 (1993) 99-104
163. Tarnawa, I., Engberg, I. and Flatman, J.A. GYKI 52466 an inhibitor of spinal reflexes is a potent quisqualate antagonist. In G. Lubec, G.A. Rosenthal (Eds) Amino Acids: Chemistry, Biology and Medicine. Escom, Leiden. 1990. pp. 538-546.
164. Tarnawa, I., Farkas, S., Berzsenyi, P., Pataki, A. and Andrasi, F. Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466. Eur. J. Pharmacol., 167 (1989) 193-199
165. Tarnawa, I., Molnár, P., Gál, L. and Andrási, F. Inhibition of hippocampal field potentials by GYKI 52466 in vitro and in vivo. Acta. Physiol. Hung., 79 (1992) 163-169
166. Turner, J.P., Leresche, N., Guyon, A., Soltesz, I. and Crunelli, V. Sensory input and burst firing output of rat and cat thalamocortical cells: the role of NMDA and non NMDA receptors. J. Physiol., 480 (1994) 281-295
167. Turski, L., Jacobsen, P., Honore, T. and Stephens, D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther., 260 (1992) 742-747
168. Tutka, P., Turski, W.A., Kleinrok, Z. and Czuczwar S.J. Influence of aminophylline and strychnine on the protective activity of excitatory amino acid antagonists against maximal electroshock-induced convulsions in mice. J. Neur. Transm., 103 (1996) 307-314.
169. Tzschentke, T.M. and Schmidt, W.J. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization. Behav. Brain Res., 84 (1997) 99-107
170. Tzschentke, T.M. and Schmidt, W.J. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA antagonist. Eur. J. Pharmacol., 295 (1996) 137-146
171. + channel block prevents the ischemia-induced release of norepinephrine from spinal cord slices. Eur. J. Pharmacol., 346 (1998) 145-150
172. Ueda, M., Oyama, T.Y., Kuraishi, Y., Akaike, A. and Satoh, M. Alpha2-adrenoceptor-mediated inhibition of capsaicin-evoked release of glutamate from rat spinal dorsal horn slices. Neurosci. Lett., 188 (1995) 137-139
173. 2A subtype of presynaptic α2-adrenoceptors modulates the release of [3H]-norepinephrine from rat spinal cord. Brain Res. Bull., 42 (1997) 129-132
174. Urban, L., Thompson, S.W.N. and Dray, A. Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci., 17 (1994) 432-438
175. Usherwood, P.N.R. and Blagbrough, I.S. Spider toxins affecting glutamate receptors: polyamines in therapeutic neurochemistry. Pharmac. Ther., 52 (1991) 245-268
176. Vanover, K.E. Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology, 136 (1998) 123-131
177. Vignes, M. and Collingridge, G.L. The synaptic activation of kainate receptors. Nature, 388 (1997) 179-182
178. Vignes, M., Bleakman, D., Lodge, D., and Collingridge, G.L. The synaptic activation of the GluR5 subtype of kainate receptor in area CA3 of the rat hippocampus. Neuropharmacology, 36 (1997) 1477-1481
179. Világi, I., Csúcs, G., Tarnawa, I. and Banczerowski-Pelyhe, I. Involvement of NMDA and non-NMDA receptors in the neocortical synaptic activation: an in vitro study on brain slices of rats of different ages. Neurosci. Lett., 232 (1996) 1-4
180. Világi, I., Kocsis, P., Tarnawa, I. and Banczerowski-Pelyhe, I. Effect of glutamate receptor antagonists on excitatory postsynaptic potentials in striatum. Brain Res. Bull., 46 (1998) 483-486
181. + activated adenosinetriphosphatase as a trigger in transmitter release. Neuroscience, 3 (1978) 367-384
182. Vizi, E.S., Somogyi, G.T., Hársing, L.G., jr. and Zimanyi, I. External Ca-independent release of norepinephrine by sympathomimetics and its role in negative feedback modulation. Proc. Natl. Acad. Sci. USA, 82 (1985) 8775-8780
183. g2+) activated ATPase, of acetylcholine release in cortical slices from rat brain. J. Physiol., 226 (1972) 95-117
184. Vizi, E.S., Mike, Á. and Tarnawa, I. 2,3-benzodiazepines (GYKI 52466 and analogs): Negative allosteric modulators of AMPA receptors. CNS Drug Rev., 2 (1996) 91-126
185. Vizi, E.S., Mike, A. and Tarnawa, I. The functional study of kainate receptors - hopes and doubts. Trends. Neurosci., 20 (1997) 396
186. Vizi, E.S. and Kiss, J.P. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and non-synaptic interactions. Hippocampus, (in press)
187. Warbinton, D. and Leander, J.D. The racemic form of LY300164, an orally effective AMPA receptor antagonist, suppresses pentylenetetrazol-induced kindling in mice. Meet. Am. Acad. Neurol, Minneapolis, 1998 (abstract)
188. Wieloch, T., Engelsen, B., Westerberg, E. and Auer, R. Lesions of the glutamatergic cortico-striatal projections in the rat ameliorate hypoglycemic brain damage in the striatum. Neurosci. Lett., 58 (1985) 25-30
189. Wilding, T.J. and Huettner, J.E. Differential antagonism of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionicacid-preferring receptors by 2,3-benzodiazepines. Molec. Pharmacol., 47 (1995) 582-587
190. Wilding, T.J. and Huettner, J.E. Activation and desensitization of hippocampal kainate receptors. J. Neurosci., 17 (1997) 2713-2721
191. Williams, R.J. and Glowinski, J. Cyclothiazide unmasks an AMPA-evoked release of arachidonic-acid from cultured striatal neurons. J. Neurochem., 67 (1996) 1551-1558
192. Wrathall, J.R., Bouzoukis, J. and Choiniere, D. Effect of kynurenate on functional deficits resulting from traumatic spinal cord injury. Eur. J. Pharmacol., 218 (1992) 2732-2781
193. Xue, D., Huang, Z.-G., Smith, K.E. and Buchan, A.M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cerebr. Blood Flow Metab., 14 (1994) 252-261
194. Yamada, K.A. and Turetsky, D.M. Allosteric interactions between cyclothiazide and AMPA/kainate receptor antagonists. British J. Pharmacol., 117 (1996) 1663-1672
195. Yamaguchi, S.-I., Donevan, S.D. and Rogawski, M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res., 15 (1993) 179-184
196. Yamamoto, C., Sawada, S. and Ohnoshosaku, T. Distribution and properties of kainate receptors distinct in the CA3 region of the hippocampus of the guinea pig. Brain Res., 783 (1998) 227-235
197. Yoshiyama, M., Roppolo, J.R. and de Groat, W.C. Effects of GYKI 52466 and CNQX, AMPA/kainate receptor antagonists, on the micturition reflex in the rat. Brain Res., 691 (1995)185-194
198. Zadow, B. and Schmidt, W.J. The AMPA antagonist NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn-Schmied. Arch. Pharmacol., 349 (1994) 61-65
199. Zhou, N., Taylor, D.A. and Parks, T.N. Cobalt-permeable non-NMDA receptors in developing chick brainstem auditory nuclei. Neuroreport, 6 (1995) 2273-2276
200. Zorumski, C.F. and Olney, J.W. Excitotoxic neuronal damage and neuropsychiatric disorders. Pharmac. Ther., 59 (1993) 145-162
201. Zorumski, C.H., Yamada, K.A., Price M.T. and Olney, J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron, 10 (1993) 61-67.